Boston Scientific Corp. announced it has closed on an additional round of financing with MValve Technologies Ltd., developer of a percutaneous mitral valve replacement system designed to work with the Boston Scientific Lotus Valve. Boston Scientific has provided the company with funding since 2012 and has an exclusive option to acquire MValve.

The Lancet published results online that show Abbott’s ARCHITECT STAT High Sensitive Troponin-I (hsTnl) test may rule out myocardial infarction (MI) in two-thirds of very-low risk patients, allowing prompt discharge from A&E (Accident and Emergency). The study identified a precise new threshold of troponin of <5 ng/L which, together with other clinical factors, allows doctors to rule out heart attacks in the majority of patients, reducing prolonged waiting for monitoring with additional tests, unnecessary procedures and hospital admissions.

Oregon Health & Science University (OHSU) now offers patients one of the most advanced computed tomography (CT) imaging systems available with the installation of Toshiba’s Aquilion ONE ViSION Edition. OHSU, a nationally prominent research university and Oregon’s only public academic medical center, acquired the new system to help improve its diagnostic capabilities for trauma, cardiac, stroke and pediatric patients. Adding the first 640-slice system in the state of Oregon allows OHSU to deliver better patient care and maintain its position as one of the leading health care institutions in the United States.

The novel Aortix device has earned a spot among the diagnostic and therapeutic modalities accepted for presentation in the Interventional Innovation “Shark Tank” Competition at the Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium. The event will be held Tuesday, Oct. 13, in San Francisco, California.